MIB1 (Ki-67) expression in non-Hodgkin's lymphomas

被引:0
|
作者
Kalogeraki, A
Tzardi, M
Panagiotides, I
Koutsoubi, K
Bolioti, S
Rontogianni, D
Stefanaki, K
Zois, E
Karidi, E
Darivianaki, K
Delides, G
Kanavaros, P
机构
[1] UNIV HOSP HERAKLION,DEPT PATHOL,ATHENS,GREECE
[2] EVANGELISMOS MED CTR,ATHENS,GREECE
[3] VENIZELION HOSP HERAKLION,ATHENS,GREECE
关键词
non-Hodgkin's lymphomas; Ki-67; MIB1; immunohistochemistry;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The MIBI monoclonal antibody which is used as a marker of cell proliferation was studied by immunohistochemistry on formalin-fixed and paraffin embedded biopsy specimens of lymph nodes in 40 high- and 46 lowgrade cases of non-Hodgkin's lymphomas (NHL) classified according to rite Kiel classification. All cases were found to display nuclear MIBI staining. A statistically significant difference (P < 0,005) was found between high- and low grade NHLs and this indicates that the high- grade NHL display a higher proliferation rate than low grade. In addition, remarkable variations in MIBI expression were found among individual cases of the same histological group. These data may suggest that MIBI index can help in the individual approach of file proliferation rate of each tumour and this may be an important parameter in association with clinical and other laboratory parameters for predicting the biological behaviour of non-Hodgkin's lymphomas.
引用
收藏
页码:487 / 491
页数:5
相关论文
共 50 条
  • [41] Prognostic impact of proliferation-associated factors MIB1 (Ki-67) and S-phase in node-negative breast cancer
    P Dettmar
    N Harbeck
    C Thomssen
    L Pache
    P Ziffer
    K Fizi
    F Jänicke
    W Nathrath
    M Schmitt
    H Graeff
    H Höfler
    British Journal of Cancer, 1997, 75 : 1525 - 1533
  • [42] MIB1/Ki67, P27/KIP1, and villin expression in hepatocellular carcinoma
    Tan, J
    Sidhu, G
    Vamvakas, E
    Yang, GC
    Wieczorek, R
    LABORATORY INVESTIGATION, 1999, 79 (01) : 168A - 168A
  • [43] THE PROGNOSTIC VALUE OF KI-67 ANTIGEN IN NON-HODGKIN LYMPHOMA OF WALDEYER RING AND THE NASAL CAVITY
    YAMANAKA, N
    HARABUCHI, Y
    KATAURA, A
    CANCER, 1992, 70 (09) : 2342 - 2349
  • [45] Hodgkin's disease and non-Hodgkin lymphomas
    Gutiérrez, EO
    REVISTA CLINICA ESPANOLA, 1999, 199 : 44 - 51
  • [46] MIB1/Ki-67 labelling index can classify grade 2 breast cancer into two clinically distinct subgroups
    Aleskandarany, Mohammed A.
    Rakha, Emad A.
    Macmillan, R. Douglas
    Powe, Desmond G.
    Ellis, Ian O.
    Green, Andrew R.
    BREAST CANCER RESEARCH AND TREATMENT, 2011, 127 (03) : 591 - 599
  • [47] MIB1/Ki-67 labelling index can classify grade 2 breast cancer into two clinically distinct subgroups
    Mohammed A. Aleskandarany
    Emad A. Rakha
    R. Douglas Macmillan
    Desmond G. Powe
    Ian O. Ellis
    Andrew R. Green
    Breast Cancer Research and Treatment, 2011, 127 : 591 - 599
  • [48] What is better/reliable, mitosis counting or Ki67/MIB1 staining?
    Kriegsmann, Mark
    Warth, Arne
    TRANSLATIONAL LUNG CANCER RESEARCH, 2016, 5 (05) : 543 - 546
  • [49] The use of Ki-67/MIB-1 immunostaining in human gliomas
    Torp, S. H.
    Mork, J. N.
    Torp, M. O.
    Skjulsvik, A. J.
    NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, 2014, 40 : 53 - 53